ACR Annual Meeting: In patients with moderate to severe systemic lupus erythematosus, anifrolumab (AstraZeneca) was superior to placebo for overall disease activity, skin disease and oral corticosteroid tapering, among other efficacy endpoints, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: At the American College of Rheumatology annual meeting in Atlanta today, Dr. Konstantinos Tselios of the University of Toronto addresses the challenges associated with developing new treatments for systemic lupus.
Availability of new dosages for hydroxychloroquine—a first-line therapy for systemic lupus—may be best for patients, shows a survey conducted by the Lupus Foundation of America.
While significant advances have been made in the treatment of systemic lupus erythematosus (SLE), the highly variable manifestations of the disease make treatment difficult.
Low-dose IL-2 might be effective and tolerated in the treatment of systemic lupus erythematosus (SLE), say researchers writing in Annals of the Rheumatic Disease this month.
Hydroxychloroquine retinopathy is more common than previously thought, shows a study published in Arthritis and Rheumatology. Higher dosages and long duration of use is associated with a higher risk of vision loss.
Reporting in the Oct. 14 issue of The American Journal of Medicine, Kristopher Ahn, M.D., and Rukma Govindu, M.D., describe a case of an otherwise healthy 36-year-old African American woman who presents to the emergency department for treatment of a long-lasting skin rash. As her ED visit unfolds, it turns into a complicated, challenging, difficult to diagnose case. Learn more in this featured case study.
A review in the journal Lupus examines treatments for primary and secondary thromboprophylaxis in patients with anti-phospholipid autoantibodies (aPL) and a history of thrombosis, which can affect more than 50 percent of people with systemic lupus erythematosus.
In a review that examines the use of conventional and orphan autoantibodies as biomarkers for diagnosing systemic lupus erythematosus (SLE), researchers say the science is advancing rapidly with the goal of diagnosing lupus earlier than currently done.
Sjögren’s syndrome secondary to systemic lupus erythematosus (SLE) rises in frequency with age, affects around one-quarter of all people with systemic lupus, and, despite less internal organ involvement than in systemic lupus without Sjögren’s syndrome, is marked by a systemic inflammatory state with high levels of pro-inflammatory cytokines, say researchers writing in The Journal of Rheumatology this month.